Abstract
Lamivudine, adefovir, telbivudine, and entecavir are nucleoside analogues that can inhibit hepatitis B virus replication and are licensed in China by the Food and Drug Administration. This study presents the cases of 2 patients who were chronically infected with HBV and suffered hepatic failure resulting from withdrawal of telbivudine and adefovir, respectively.
Acknowledgements
We thank Prof. Qiurong Ruan who gave a precise and accurate description of the pathological sections.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.